Cytovia.png
Olivier Gouédard, PharmD, MBA joins Cytovia Therapeutics as Chief Operating Officer
June 22, 2021 08:55 ET | Cytovia Therapeutics
CAMBRIDGE, Mass. and AVENTURA, Fla., June 22, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Chimeric Antigen...
Cytovia.png
William Sullivan, CPA, MBA joins Cytovia Therapeutics as Chief Financial Officer
June 15, 2021 13:21 ET | Cytovia Therapeutics
CAMBRIDGE, Mass. and AVENTURA, Fla., June 15, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Chimeric Antigen...
Cytovia.png
Cytovia Therapeutics CEO Dr. Daniel Teper to Present at Two Upcoming Conferences
May 14, 2021 10:58 ET | Cytovia Therapeutics
CAMBRIDGE, Mass. and AVENTURA, Fla., May 14, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Chimeric Antigen...
Cytovia.png
Cytovia Therapeutics Expands Leadership Team
May 13, 2021 09:48 ET | Cytovia Therapeutics
Jason Aryeh elected to Board of DirectorsElizabeth Schwarzbach, PhD and Boris Reznik, PhD join Strategic Advisory BoardElysa Mantel appointed as Vice President, General Counsel and Corporate Secretary...
Cytovia.png
Stanley R. Frankel, MD, FACP joins Cytovia Therapeutics as Chief Medical Officer
April 28, 2021 13:16 ET | Cytovia Therapeutics
CAMBRIDGE, Mass. and AVENTURA, Fla., April 28, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Chimeric Antigen...
Cytovia.png
Cytovia Therapeutics Files New Patents for its Natural Killer Cell Engager Multifunctional Antibodies (FLEX-NK®) for the Treatment of Hematological and Solid Tumors
April 12, 2021 11:11 ET | Cytovia Therapeutics
CAMBRIDGE, Mass. and AVENTURA, Fla., April 12, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Chimeric Antigen...
Cytovia.png
Cytovia Therapeutics Opens Boston R&D Center of Excellence and Announces cGMP Manufacturing Facility, Aiming to Start Clinical Trials for its Gene-Edited iPSC CAR-NK Cells by 2022
March 17, 2021 09:39 ET | Cytovia Therapeutics
R&D labs for NK cell biology, gene-editing, antibody and CAR development, and NK cell pilot manufacturing opens in Natick, MACell therapy manufacturing facility with best-in-industry clinical and...
Cytovia.png
Cytovia Therapeutics’ Management to Present at Three Upcoming Conferences in March
March 08, 2021 10:24 ET | Cytovia Therapeutics
CAMBRIDGE, Mass., March 08, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Natural Killer (NK) and Chimeric...
Cytovia.png
Cytovia Therapeutics Partners with National Cancer Institute to Develop Novel Gene-Edited, iPSC-Derived GPC3 CAR NK Cells for the Treatment of Solid Tumors
January 13, 2021 07:47 ET | Cytovia Therapeutics
CAMBRIDGE, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, an emerging biopharmaceutical company focusing on Natural Killer cells in cancer, announced today that it has signed a...
Cytovia.png
Cytovia Therapeutics announces plans to initiate in 2021 Clinical Development of Universal iPSC NK Cell Therapy for Hematological and Solid Tumors
December 08, 2020 09:04 ET | Cytovia Therapeutics
CAMBRIDGE, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, an emerging NK cell therapeutics company, announced today that it plans to file with the FDA in 2021 an Investigational New...